VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a report published on Sunday morning. The firm issued a sell rating on the stock.

Other research analysts have also recently issued reports about the stock. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of VolitionRx in a report on Tuesday, December 10th.

VolitionRx Price Performance

VNRX stock opened at $0.65 on Friday. The firm has a 50 day simple moving average of $0.66 and a two-hundred day simple moving average of $0.66. The stock has a market cap of $60.05 million, a PE ratio of -1.80 and a beta of 1.17. VolitionRx has a one year low of $0.43 and a one year high of $1.23.

Insiders Place Their Bets

In other news, CEO Cameron John Reynolds purchased 139,811 shares of the business’s stock in a transaction on Monday, December 9th. The shares were acquired at an average price of $0.57 per share, with a total value of $79,692.27. Following the acquisition, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Guy Archibald Innes acquired 174,764 shares of the stock in a transaction dated Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, with a total value of $99,615.48. Following the completion of the purchase, the director now owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. The trade was a 39.51 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 358,266 shares of company stock valued at $204,212 in the last ninety days. Company insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC grew its stake in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.